Sleijfer S, van der Mark T W, Schraffordt Koops H, Mulder N H
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
Eur J Cancer. 1996 Mar;32A(3):550-2. doi: 10.1016/0959-8049(95)00644-3.
We examined whether cisplatin-induced nephrotoxicity augmented bleomycin-induced pulmonary toxicity in patients with testicular cancer treated with etoposide and cisplatin with (BEP) or without bleomycin (EP). Before and at 3-week intervals during chemotherapy, creatinine clearance and lung functions were measured. In patients receiving BEP, deterioration of renal function correlated with a decrease in transfer factor of the lungs for carbon monoxide (TLCO) and vital capacity (VC), parameters known to reflect bleomycin-induced pulmonary effects. Other lung functions did not correlate with renal function. In the EP group, no relationships were observed at all. These observations suggest enhanced pulmonary effects of bleomycin when combined with cisplatin. Therefore, attention should be paid to the potential development of bleomycin-induced pulmonary toxicity in patients treated with BEP.
我们研究了在接受依托泊苷和顺铂联合(BEP)或不联合博来霉素(EP)治疗的睾丸癌患者中,顺铂诱导的肾毒性是否会增强博来霉素诱导的肺毒性。在化疗前及化疗期间每隔3周,测量肌酐清除率和肺功能。在接受BEP治疗的患者中,肾功能恶化与反映博来霉素诱导肺效应的参数——肺一氧化碳转运因子(TLCO)和肺活量(VC)降低相关。其他肺功能与肾功能无相关性。在EP组中,未观察到任何相关性。这些观察结果表明,博来霉素与顺铂联合使用时,其肺效应增强。因此,对于接受BEP治疗的患者,应关注博来霉素诱导肺毒性的潜在发展。